Natasha N Kyte, MD
Internal Medicine · Berkeley
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 7
Offices
7 locations · Sutter Bay Medical Foundation · Golden Valley Health Centers
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center - Alta Bates Camp · Eden Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kyte’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A148820 · Current
Licensed to practise in California · since 2017 · expires 2028-05-31 · Southern Illinois University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Eden Medical CenterCastro Valley, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.122, Oct 2024 – Sep 2025
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Eden Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.122 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.88 (0 to 1.89) · 819 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.46 to 1.16) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 137.41 (92.94 to 181.88) · 70 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.4 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 38 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.1 · 207 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.6 · 359 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 355 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 1,714 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0 to 0.39) · 4,697 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.1 to 0.5) · 4,676 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.69 (0.53 to 4.85) · 860 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.56 (0 to 3.24) · 251 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.75 (1.17 to 4.32) · 818 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.76 (0 to 15.78) · 261 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 242 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.64 (0.16 to 3.12) · 233 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.85) · 4,132 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.431 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.292 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.307 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.61 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 258 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 22.6 · 225 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 2.4 · 367 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 390 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 58 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 88 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.9 (9.6 to 17.4) · 68 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.1) · 205 cases | No different | Jan 2024 – Dec 2024 |
What patients said (431 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$24,728
Medicare paid this office $24,728 for 284 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 128 | $8,880 | $65 |
| Return visit (30+ min) | 92 | $8,545 | $86 |
| New patient visit (45+ min) | 18 | $2,078 | $115 |
| New patient visit (30+ min) | 23 | $1,763 | $77 |
| Detection test by immunoassay technique for streptococcus, group a (strep) | 29 | $478 | $16 |
See all 11 services
| Short return visit (20+ min) | 128 | $8,880 | $65 |
| Return visit (30+ min) | 92 | $8,545 | $86 |
| New patient visit (45+ min) | 18 | $2,078 | $115 |
| New patient visit (30+ min) | 23 | $1,763 | $77 |
| Detection test by immunoassay technique for streptococcus, group a (strep) | 29 | $478 | $16 |
| Short return visit | 11 | $461 | $42 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 24 | $389 | $16 |
| Injection of drug or substance under skin or into muscle | 23 | $305 | $11 |
| Automated urinalysis test | 57 | $128 | $2 |
| Blood glucose (sugar) test performed by hand-held instrument | 13 | $42 | $3 |
| Injection, ceftriaxone sodium, per 250 mg | 12 | $21 | None |
Who their Medicare patients are
284 Original Medicare patients in 2024. Average age 72 · Under 65 11% · 85 and older 10% · Women 61% · Also on Medicaid 23% · Health risk score 1.20. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 72% · Diabetes 34% · Chronic kidney disease 26% · Depression 24% · Coronary heart disease 22% · Atrial fibrillation 18% · COPD 14% · Heart failure 12% · Cancer 10% · Stroke 8%.
The office billed $104,693, Medicare allowed $35,406 and paid $24,728; for 635 services of 44 kinds; $242 of it was for drugs given in the office and $24,486 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 284 | 635 | 72 | 1.20 | $104,693 | $24,728 |
| 2023 | 461 | 1,092 | 73 | 1.14 | $171,654 | $51,402 |
| 2022 | 515 | 1,114 | 73 | 1.19 | $171,316 | $54,998 |
| 2021 | 505 | 1,065 | 72 | 1.12 | $163,260 | $52,501 |
| 2020 | 464 | 1,066 | 72 | 1.39 | $135,195 | $36,403 |
| 2019 | 220 | 820 | 70 | 1.50 | $179,943 | $45,699 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Return visit (30+ min) | 219 | $23,863 | $102 |
| Short return visit (20+ min) | 113 | $7,417 | $66 |
| Sarscov2 vac 50 mcg/0.5ml im | 29 | $4,147 | $143 |
| New patient visit (45+ min) | 34 | $3,882 | $114 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 30 | $2,274 | $76 |
| New patient visit (30+ min) | 26 | $2,129 | $82 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 81 | $1,328 | $16 |
| Admn sarscov2 vacc 1 dose | 29 | $1,243 | $43 |
| Administration of influenza virus vaccine | 29 | $932 | $32 |
| Short return visit | 16 | $698 | $44 |
| Injection of drug or substance under skin or into muscle | 23 | $512 | $12 |
| Automated urinalysis test | 80 | $185 | $2 |
2022: 15 services
| Return visit (30+ min) | 247 | $27,856 | $104 |
| Short return visit (20+ min) | 175 | $14,547 | $81 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 39 | $2,740 | $70 |
| New patient visit (45+ min) | 19 | $2,500 | $132 |
| Administration of influenza virus vaccine | 39 | $1,214 | $31 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 57 | $945 | $16 |
| Injection of drug or substance under skin or into muscle | 30 | $736 | $12 |
| Short return visit | 12 | $568 | $47 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 24 | $271 | $11 |
| Automated urinalysis test | 71 | $162 | $2 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 19 | $145 | $8 |
| Blood glucose (sugar) test performed by hand-held instrument | 16 | $52 | $3 |
| Insertion of needle into vein for collection of blood sample | 12 | $35 | $3 |
| Injection, ketorolac tromethamine, per 15 mg | 13 | $27 | None |
| Injection, promethazine hcl, up to 50 mg | 11 | $26 | None |
2021: 17 services
| Return visit (30+ min) | 224 | $26,444 | $106 |
| Short return visit (20+ min) | 202 | $14,994 | $73 |
| Influenza vaccine split virus, preservative free | 38 | $2,419 | $64 |
| New patient visit (45+ min) | 15 | $2,112 | $141 |
| New patient visit (30+ min) | 13 | $1,086 | $84 |
| Injection of drug or substance under skin or into muscle | 33 | $893 | $12 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 13 | $667 | $51 |
| Short return visit | 13 | $609 | $47 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 18 | $298 | $17 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 23 | $250 | $11 |
| Automated urinalysis test | 67 | $169 | $2 |
| Injection, meperidine hydrochloride, per 100 mg | 11 | $138 | None |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 15 | $124 | $8 |
| Blood glucose (sugar) test performed by hand-held instrument | 18 | $59 | $3 |
| Injection, promethazine hcl, up to 50 mg | 13 | $58 | None |
| Injection, ketorolac tromethamine, per 15 mg | 12 | $24 | None |
| Injection, ceftriaxone sodium, per 250 mg | 11 | $19 | None |
2020: 12 services
| Short return visit (20+ min) | 321 | $20,178 | $55 |
| Return visit (30+ min) | 86 | $8,041 | $86 |
| Influenza vaccine split virus, preservative free | 36 | $2,195 | $61 |
| New patient visit (30+ min) | 12 | $1,133 | $94 |
| Injection of drug or substance under skin or into muscle | 40 | $1,016 | $11 |
| Administration of influenza virus vaccine | 43 | $759 | $18 |
| Hemoglobin a1c level | 14 | $133 | $10 |
| Automated urinalysis test | 37 | $88 | $2 |
| Injection, morphine sulfate, up to 10 mg | 11 | $52 | None |
| Injection, promethazine hcl, up to 50 mg | 16 | $46 | None |
| Injection, ketorolac tromethamine, per 15 mg | 17 | $46 | None |
| Injection, ceftriaxone sodium, per 250 mg | 12 | $35 | None |
2019: 9 services
| Short return visit (20+ min) | 142 | $15,084 | $58 |
| Return visit (30+ min) | 93 | $9,826 | $85 |
| New patient visit (30+ min) | 89 | $6,945 | $78 |
| Short return visit | 87 | $4,580 | $36 |
| Influenza vaccine, inactivated | 35 | $1,984 | $57 |
| New patient visit (45+ min) | 14 | $1,799 | $129 |
| Administration of influenza virus vaccine | 40 | $693 | $17 |
| New patient visit (15+ min) | 11 | $627 | $57 |
| Administration of pneumococcal vaccine | 18 | $312 | $17 |
Medicaid work
$1,038 in 2020
Medicaid paid $1,038 for 104 billed services this clinician did in 2020, up to 62 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 104 | $1,038 |
| 2020 | 104 | 1 | 62 | $1,038 |
| 2019 | 230 | 4 | 36 | $1,106 |
See the largest Medicaid services in earlier years
2019
| New patient visit (30+ min) | 26 | $388 |
| Short return visit | 86 | $350 |
| Short return visit (20+ min) | 93 | $311 |
| Return visit (30+ min) | 25 | $56 |
Drugs they prescribed that Part D paid
$2,128
Pharmacies billed $2,128 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
175 generic and 12 brand-name prescriptions · $2,128 in drug cost · 109 antibiotic prescriptions to 99 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Amoxicillin-Clavulanate Potass | 19 | $190 | $10 |
| Cephalexin | 25 | $161 | $6 |
| Azithromycin | 21 | $45 | $2 |
| Amoxicillin | 11 | $41 | $4 |
Year by year
| 2024 | 187 | 155 | None | 6% | $2,128 |
| 2023 | 328 | 251 | None | None | $5,573 |
| 2022 | 256 | 203 | None | None | $4,874 |
| 2021 | 200 | 164 | None | None | $3,737 |
| 2020 | 640 | 198 | 2% (15) | None | $56,468 |
| 2019 | 1,096 | 196 | 2% (17) | 17% | $71,631 |
| 2018 | 1,056 | 199 | 7% (76) | 18% | $46,658 |
| 2017 | 131 | 59 | None | None | $8,470 |
| 2016 | 181 | 48 | None | None | $12,917 |
| 2014 | 60 | 32 | None | None | $4,991 |
| 2013 | 35 | 16 | None | None | $1,150 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Cephalexin | 50 | $441 | $9 |
| Amoxicillin-Clavulanate Potass | 29 | $285 | $10 |
| Doxycycline Monohydrate | 15 | $192 | $13 |
| Azithromycin | 33 | $179 | $5 |
| Amoxicillin | 25 | $111 | $4 |
| Mupirocin | 11 | $98 | $9 |
2022: 7 drugs
| Doxycycline Monohydrate | 20 | $304 | $15 |
| Cephalexin | 42 | $299 | $7 |
| Amoxicillin-Clavulanate Potass | 15 | $172 | $11 |
| Azithromycin | 20 | $144 | $7 |
| Mupirocin | 11 | $107 | $10 |
| Ciprofloxacin | 11 | $95 | $9 |
| Prednisone | 16 | $57 | $4 |
2021: 2 drugs
| Cephalexin | 48 | $267 | $6 |
| Amoxicillin-Clavulanate Potass | 11 | $112 | $10 |
2020: 14 drugs
| Levothyroxine | 25 | $607 | $24 |
| Atorvastatin | 26 | $339 | $13 |
| Gabapentin | 20 | $269 | $13 |
| Omeprazole | 18 | $259 | $14 |
| Losartan | 32 | $210 | $7 |
| Trazodone | 21 | $183 | $9 |
| Metformin | 25 | $142 | $6 |
| Amlodipine Besylate | 25 | $129 | $5 |
| Amoxicillin-Clavulanate Potass | 12 | $114 | $9 |
| Lisinopril | 16 | $113 | $7 |
| Alendronate | 11 | $91 | $8 |
| Hydrochlorothiazide | 13 | $72 | $6 |
| Cephalexin | 17 | $70 | $4 |
| Metoprolol | 12 | $37 | $3 |
2019: 25 drugs
| Duloxetine | 17 | $1,730 | $102 |
| Ventolin Hfa | 15 | $1,185 | $79 |
| Levothyroxine | 55 | $1,104 | $20 |
| Gabapentin | 46 | $890 | $19 |
| Atorvastatin | 41 | $883 | $22 |
| Trazodone | 51 | $556 | $11 |
| Hydralazine | 19 | $367 | $19 |
| Amlodipine Besylate | 41 | $302 | $7 |
| Celecoxib | 14 | $297 | $21 |
| Omeprazole | 16 | $270 | $17 |
| Lisinopril | 32 | $263 | $8 |
| Simvastatin | 25 | $246 | $10 |
| Losartan | 23 | $237 | $10 |
| Metformin | 44 | $224 | $5 |
| Alendronate | 21 | $209 | $10 |
| Hydrocodone-Acetaminophen | 13 | $195 | $15 |
| Quetiapine | 12 | $166 | $14 |
| Famotidine | 18 | $160 | $9 |
| Hydrochlorothiazide | 28 | $152 | $5 |
| Atenolol | 18 | $151 | $8 |
| Warfarin | 13 | $143 | $11 |
| Clopidogrel | 12 | $122 | $10 |
| Glipizide | 20 | $117 | $6 |
| Metoprolol | 22 | $107 | $5 |
| Citalopram Hbr | 11 | $62 | $6 |
2018: 27 drugs
| Advair Diskus | 15 | $6,532 | $435 |
| Atorvastatin | 61 | $1,759 | $29 |
| Ventolin Hfa | 29 | $1,375 | $47 |
| Levothyroxine | 50 | $1,327 | $27 |
| Gabapentin | 41 | $1,205 | $29 |
| Losartan | 40 | $562 | $14 |
| Acetaminophen-Codeine | 23 | $555 | $24 |
| Hydrocodone-Acetaminophen | 38 | $496 | $13 |
| Lisinopril | 35 | $425 | $12 |
| Allopurinol | 12 | $358 | $30 |
| Ibuprofen | 24 | $346 | $14 |
| Amlodipine Besylate | 45 | $332 | $7 |
| Famotidine | 16 | $283 | $18 |
| Atenolol | 24 | $274 | $11 |
| Metoprolol | 28 | $266 | $9 |
| Omeprazole | 11 | $265 | $24 |
| Hydrochlorothiazide | 24 | $251 | $10 |
| Montelukast | 17 | $250 | $15 |
| Glipizide | 18 | $244 | $14 |
| Lisinopril-Hydrochlorothiazide | 19 | $225 | $12 |
| Metformin | 18 | $213 | $12 |
| Fluticasone Propionate | 15 | $191 | $13 |
| Alendronate | 13 | $165 | $13 |
| Simvastatin | 14 | $154 | $11 |
| Carvedilol | 13 | $139 | $11 |
| Prednisone | 11 | $137 | $12 |
| Trazodone | 13 | $101 | $8 |
2016: 2 drugs
| Atorvastatin | 14 | $164 | $12 |
| Metformin | 16 | $81 | $5 |
Professional record
- NPI
- 1790129427
- Licence
- CA A148820California A148820: Current · expires 2028-05-31
- Trained
- Southern Illinois University School of Medicine, 2013
- Group
- Sutter Bay Medical Foundation · Golden Valley Health Centers
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- Po Box 255228, Sacramento, CA, 95865
- NPI first listed
- 2013-04-24
- NPI last updated
- 2020-03-05
- NPI record certified
- 2020-03-05
This is when the NPI record was last certified, not a medical board exam.